- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06131801
Farmacokinetisch onderzoek van Venetoclax-tabletten vermalen en opgelost in een oplossing
Een farmacokinetisch onderzoek naar Venetoclax-tabletten, vermalen en opgelost in een oplossing bij kinderen en jongvolwassenen met hematologische maligniteiten
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.
Primary Objectives
• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution
Secondary Objectives
- To evaluate the safety of crushed venetoclax tablets administered as an oral solution
- To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors
- To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)
- To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution
Studie Overzicht
Toestand
Conditie
- Lymfoom
- Folliculair lymfoom
- Leukemie
- B-cel lymfoom
- Hodgkin lymfoom
- Burkitt lymfoom
- AML
- Non-Hodgkin lymfoom
- Acute lymfatische leukemie
- Acute myeloïde leukemie
- Diffuus grootcellig B-cellymfoom
- Hematologische maligniteit
- Chronische myelogene leukemie
- Myeloproliferatief neoplasma
- T-cel lymfoom
- Perifeer T-cellymfoom
- CML
- ALLE
- Cutaan B-cellymfoom
Gedetailleerde beschrijving
Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Site Public Contact
- Telefoonnummer: (513) 636-2799
- E-mail: cancer@cchmc.org
Studie Locaties
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- Children's Hospital Colorado
-
Hoofdonderzoeker:
- Kelly Faulk, MD
-
Contact:
- Kelly Faulk, MD
- Telefoonnummer: 720-777-5771
- E-mail: Kelly.Faulk@childrenscolorado.org
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30329
- Nog niet aan het werven
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital
-
Contact:
- Himalee Sabnis, MD, MS
- Telefoonnummer: 57922 404-785-3627
- E-mail: Himalee.sabnis@choa.org
-
Hoofdonderzoeker:
- Himalee Sabnis, MD, MS
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Werving
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Children's Hospital of Philadelphia
-
Hoofdonderzoeker:
- Sarah Tasian, MD
-
Contact:
- Tasleema Patel
- Telefoonnummer: 917-818-6971
- E-mail: patelt6@chop.edu
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Texas Children's Hospital
-
Contact:
- Michelle Redell, MD
- Telefoonnummer: 832-822-4242
- E-mail: mlredell@texaschildrens.org
-
Contact:
- Grace Anand
- Telefoonnummer: 832-824-7705
- E-mail: gxanand@texaschildrens.org
-
Hoofdonderzoeker:
- Michelle Redell, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Werving
- Children's Hospital of Wisconsin
-
Hoofdonderzoeker:
- Zachary Graff, MD
-
Contact:
- Kira Mielke
- E-mail: kmielke@mcw.edu
-
Contact:
- Kara Nelson
- E-mail: knelson@mcw.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
Patients must be <39 years of age at time of study enrollment.
Beschrijving
Inclusion Criteria:
- Age: Patients must be <39 years of age at time of study enrollment
- Diagnosis: Patients may have a diagnosis of any hematologic malignancy
- Central access: Patients must have an existing venous or arterial access line for PK blood draws
- Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment
- Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
- Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.
Exclusion Criteria:
- Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.
- Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: OTHER
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Children and Young Adults
Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care. |
Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the observed peak plasma concentration (Cmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the time to peak (Tmax) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the apparent terminal phase elimination rate constant (β) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the terminal-phase elimination half-life (T1/2) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)
Tijdsspanne: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
PK parameters of venetoclax will be described in peripheral blood including: oral clearance (CL/F) of venetoclax |
Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the observed peak plasma concentration (Cmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the time to peak (Tmax) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the apparent terminal phase elimination rate constant (β) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the terminal-phase elimination half-life (T1/2) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
|
Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)
Tijdsspanne: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
PK parameters of venetoclax will be described in cerebral spinal fluid including: oral clearance (CL/F) |
Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Chronische ziekte
- Ziekte attributen
- Ziekten van het immuunsysteem
- Infecties
- Virusziekten
- Neoplasmata per histologisch type
- Hematologische ziekten
- DNA-virusinfecties
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Leukemie, myeloïde
- Beenmergziekten
- Leukemie, Lymfoïde
- Epstein-Barr-virusinfecties
- Herpesviridae-infecties
- Tumorvirusinfecties
- Pathologische aandoeningen, tekenen en symptomen
- Hemische en lymfatische ziekten
- Leukemie
- Leukemie, myeloïde, acuut
- Hematologische neoplasmata
- Lymfoom
- Lymfoom, B-cel
- Lymfoom, grote B-cel, diffuus
- Voorlopercel lymfoblastische leukemie-lymfoom
- Burkitt lymfoom
- Lymfoom, non-Hodgkin
- Lymfoom, folliculair
- Myeloproliferatieve aandoeningen
- Ziekte van Hodgkin
- Lymfoom, T-cel
- Lymfoom, T-cel, perifeer
- Leukemie, Myelogeen, Chronisch, BCR-ABL Positief
Andere studie-ID-nummers
- Venetoclax PK
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .